GlobeNewsWire
12 Aug 2026, 12:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
AIM ImmunoTech is positioning its drug Ampligen as a potential broad-spectrum prophylactic or early-onset antiviral countermeasure for Ebola and its variants. — Opening a new potential application in biodefense expands the drug's addressable market and potential for government procurement contracts.
+0.40CEO Thomas K. Equels is advocating for the US government to evaluate and procure biodefense countermeasures like Ampligen before novel threats emerge. — Strategic lobbying for a shift in procurement policy could lead to non-dilutive government funding, though it is currently just an opinion piece.
+0.20Which stocks this story touches
The company is promoting the potential of its drug Ampligen for biodefense and Ebola treatment via a CEO-authored article.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
11h ago
